The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients

BackgroundTumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also analyzed the prognostic value of the localization of CD163+ and CD68+ myeloid cells in human breast cancer.MethodsThe extent of infiltrating CD163+ or CD68+ myeloid cells in tumor nest versus tumor stroma was evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s Rho and χ2 tests were used to examine the correlations between CD163+ or CD68+ myeloid cells and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the impact of CD163+ and CD68+ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free survival, breast cancer specific and overall survival.ResultsWe found that infiltration of CD163+ and CD68+ macrophages into tumor stroma, but not into tumor nest, were of clinical relevance. CD163+ macrophages in tumor stroma positively correlated with higher grade, larger tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like breast cancer and inversely correlated with luminal A breast cancer. Some CD163+ areas lacked CD68 expression, suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact. CD68+ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast cancer specific survival.ConclusionThese findings highlight the importance of analyzing the localization rather than merely the presence of TAMs as a prognostic marker for breast cancer patients.

[1]  T. Langmann,et al.  Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro‐ and antiinflammatory stimuli , 2000, Journal of leukocyte biology.

[2]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[3]  Anne E Carpenter,et al.  Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. , 2011, The Journal of clinical investigation.

[4]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[6]  G. Soma,et al.  Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. , 2004, Anticancer research.

[7]  S. Moestrup,et al.  CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. , 2006, Immunobiology.

[8]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[9]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[10]  L. Esserman,et al.  Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome , 2011, Breast Cancer Research and Treatment.

[11]  L. Happerfield,et al.  Angiogenesis and inflammation in invasive carcinoma of the breast. , 1997, Journal of clinical pathology.

[12]  P. Chu,et al.  CD163: a specific marker of macrophages in paraffin-embedded tissue samples. , 2004, American journal of clinical pathology.

[13]  K. Jirström,et al.  Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer , 2012, Acta oncologica.

[14]  Dennis B. Troup,et al.  NCBI GEO: mining millions of expression profiles—database and tools , 2004, Nucleic Acids Res..

[15]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[16]  R. Hawkins,et al.  Oestrogen receptor concentration and macrophage infiltration in human breast cancer. , 1986, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[18]  R. Vink,et al.  The prognostic value of tumour-stroma ratio in triple-negative breast cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[20]  D. Simmons,et al.  Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. , 1993, Blood.

[21]  K. Jirström,et al.  Chondroitin sulfate expression predicts poor outcome in breast cancer. , 2011, International journal of oncology.

[22]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[23]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[24]  P. Tak,et al.  Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. , 2012, Journal of immunological methods.

[25]  G. Soma,et al.  The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. , 2003, Anticancer research.

[26]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[27]  H. Møller,et al.  Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Tudung T Nguyen,et al.  Expression of CD163 (Hemoglobin Scavenger Receptor) in Normal Tissues, Lymphomas, Carcinomas, and Sarcomas Is Largely Restricted to the Monocyte/Macrophage Lineage , 2005, The American journal of surgical pathology.

[29]  William M Gallagher,et al.  Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer , 2010, BMC Cancer.

[30]  J. Bergh,et al.  Identification of molecular apocrine breast tumours by microarray analysis , 2005, Breast Cancer Research.

[31]  M. Ellis,et al.  Pathology Parameters and Adjuvant Tamoxifen Response in a Randomised Premenopausal Breast Cancer Trial , 2006 .

[32]  Dirk Nagorsen,et al.  Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival , 2007, Journal of Translational Medicine.